FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:306-307 January 15, 2009 Number 3 Next

An -Melanocyte–Stimulating Hormone Analogue in Erythropoietic Protoporphyria

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Patients with erythropoietic protoporphyria, a rare inherited disease, accumulate photosensitizing protoporphyrin in the dermis, which results in severe dermal pain and incapacitating phototoxic reactions when the skin is exposed to visible light, primarily blue light (the Soret band, with the strongest absorbance among the porphyrins).¹ Current treatments are partially effective at best (unpublished data). A beneficial effect of melanogenesis induced by natural sunlight or by ultraviolet radiation has been described in anecdotal reports.^2,3

Afamelanotide (Nle⁴-D-Phe⁷–-melanocyte–stimulating hormone, formerly called CUV1647) is an -melanocyte–stimulating hormone analogue that induces epidermal melanin formation.⁴ Here, we describe the responses . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.